Abstract / Description
Background and objectivesThe role of pretreatment serum α-hydroxybutyrate dehydrogenase (α-HBDH) in small cell lung cancer (SCLC) prognosis prediction remains unknown. We sought to investigate the influence of pretreatment α-HBDH level on the survival of patients with SCLC.MethodsThe serum concentration of α-HBDH was measured in 400 SCLC patients. The correlations between pretreatment serum α-HBDH concentration and clinicopathological characteristics were analysed. Univariate and multivariate Cox regression analyses were used to evaluate the relationships between α-HBDH levels and the progression-free survival (PFS) and overall survival (OS) of SCLC patients.ResultsPretreatment α-HBDH levels were closely associated with tumour stage, NSE levels, LDH levels, and surgical treatment. Patients with high α-HBDH were more likely to have extensive disease, high NSE levels, and high LDH levels (